Preclinical Potency and Safety Studies of an AAV2-Mediated Gene Therapy Vector for the Treatment of <i>MERTK</i> Associated Retinitis Pigmentosa
Thomas J. Conlon(Adelson Foundation), William W. Hauswirth(University of Florida), Travis Cossette(University of Florida), Brian Cleaver(University of Florida), Issam McDoom(University of Florida), Marc C. Peden(University of Florida), Renee C. Ryals(University of Alabama at Birmingham), Kirsten Erger(University of Florida), Wen‐Tao Deng(University of Florida), Mark B. Sherwood, Fowzan S. Alkuraya(Alfaisal University), Corinne R. Abernathy(University of Florida), Nathalie Clément(University of Florida), Ji‐Jing Pang(University of Florida), Sanford L. Boye(University of Florida)
Cited by 95
Related Papers
Treatment of Leber Congenital Amaurosis Due to <i>RPE65</i> Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial
|Human Gene Therapy|2008|950
Recombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction In Vivo
|Circulation Research|2006|400
Mutational Analysis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Construction of AAV2 Vectors with Altered Tropism
|Journal of Virology|2000|392